OmniAb (OABI) Q3 2026 earnings review
OmniAb adds partner cash, but quarterly milestone sales pause
OmniAb brought in a wave of upfront partner cash even as its quarterly revenue dropped back to earth. The provider of antibody-discovery tools reported $4 million in third-quarter sales, up 78% from a year ago on research services and lab machine sales, while a new license deal with Eli Lilly lifted cash to $64 million. Chief executive Matt Foehr raised the full-year outlook again, though by our math the plan points to fourth-quarter revenue falling 38% from a year ago.
| Revenue | $4.0M +78% from a year ago, -70% from last quarter |
|---|---|
| Total deferred revenue | $15.0M up from $2.6M last quarter (by our math) |
| Cash and short-term investments | $64.2M up $12.2M from last quarter |
| Full-year revenue outlook | Raised $3M middle of the range: $37M (+98%) |
⚖️ Verdict: 🟢 Bullish
The story got better because the Eli Lilly agreement replenished the balance sheet and locked in $15 million of future service work, removing near-term funding worries. The company also opened its xPloration screening machine to all buyers and set a target for sales to double in 2027 and 2028. One caution: milestone payments dropped to almost zero this quarter, showing that OmniAb still loses about $16 million a quarter whenever partner payouts pause.
The question now is whether rising service work and lab machine sales can smooth out the gaps between lumpy partner milestones. Either outside buyers adopt xPloration at the pace management projects, or the business stays reliant on unpredictable clinical trial payouts to cover its $52 million annual cash costs. Fourth-quarter machine sales and the initial 2027 revenue outlook will tell.
🐂 Bull Case
Eli Lilly Deal Lifts Cash and Deferred Revenue
OmniAb licenses genetically modified animals that help drugmakers discover human antibodies, earning upfront payments, research fees, and future royalties. In the third quarter, the biotechnology company signed a global collaboration and license agreement with Eli Lilly "for a new ion channel program", which targets proteins that control electrical signals in cells. That deal included an undisclosed upfront payment and up to $370 million in future milestones.
- Total deferred revenue: $15.0 million, up from $2.6 million in the second quarter by our math
- Cash and short-term investments: $64.2 million, up $12.2 million from last quarter by our math
- Full-year revenue outlook: raised by $3 million at the middle of the range to $35–39 million
The upfront cash went onto the balance sheet as deferred revenue—cash customers have paid for work not yet performed—because OmniAb recognizes it as it delivers research services. Collection of earlier milestone bills also cut accounts receivable by $4.8 million since December. Together, those inflows prompted chief executive Matt Foehr to raise the full-year year-end cash outlook to $53–57 million.
What to watch: service revenue over the next four quarters. As researchers complete work on the Eli Lilly program, that $15.0 million deferred balance will turn into recognized service revenue and reduce quarterly cash burn.
xPloration Opens to All Buyers With Multi-Year Targets
OmniAb sells xPloration, a laboratory machine that uses artificial intelligence to screen single immune cells for drug candidates, alongside single-use chemical kits. Previously, only existing licensing partners could buy the system. In October, the Emeryville group made the machine "available for purchase by all customers beginning in October 2026" and gave its first multi-year revenue forecast for the product.
Third-quarter xPloration sales reached $703 thousand, up from $74 thousand a year ago, with gross margin at 56% after deducting $309 thousand in manufacturing costs by our math. Management expects the product to bring in $2–3 million in 2026, which leaves about $582 thousand for the fourth quarter at the middle of the range, and "expects xPloration revenue to double in 2027 and to double again in 2028".
What to watch: fourth-quarter xPloration revenue against the $582 thousand implied target. Hitting $8–12 million by 2028 requires steady machine placements with outside buyers, not just existing partners.
Partner Clinical Wins Advance Future Milestones
OmniAb makes most of its high-margin revenue when drugmakers advance antibodies discovered on its platform through human trials. Several partners reported clinical progress during the third quarter and October. Teva Pharmaceuticals said its antibody TEV-'408 met its main goal in a Phase 2a celiac disease study, preventing intestinal damage from gluten without safety issues.
Meanwhile, China's drug regulator approved Harbour BioMed's batoclimab injection for generalized myasthenia gravis, a muscle-weakness disorder, and Merck KGaA continued a Phase 3 colorectal cancer trial for its antibody-drug conjugate. These steps matter because late-stage trial starts and regulatory approvals trigger larger payouts from the company's pool of over $340 million in clinical milestones.
What to watch: Immunovant's update on IMVT-1402 in hard-to-treat rheumatoid arthritis, scheduled for the second half of 2026. Positive progress there keeps multiple late-stage shots on goal for 2027 and 2028 readouts.
🐻 Bear Case
Milestone Drought Drops Quarterly Revenue
Chief executive Matt Foehr said third-quarter progress and new products "reinforce our confidence in the durability of our revenue base and our long-term growth potential". The quarterly income statement shows that top-line results still swing wildly with partner milestone timing.
- Third-quarter license and milestone revenue: $100 thousand, down from $9.5 million in the second quarter
- Third-quarter total revenue: $4.0 million, down 70% from the second quarter by our math
- Fourth-quarter revenue implied by the full-year outlook: $5.2 million at the middle of the range, down 38% from a year ago by our math
First-half revenue surged because delayed 2025 milestones landed early in 2026, bringing nine-month milestone revenue to $21.6 million. With almost no milestone payments in the third quarter, total sales fell back to the underlying service and instrument run rate. Even after raising the full-year revenue forecast by $3 million, the plan implies fourth-quarter sales of $3.2–7.2 million, well below last year's $8.4 million.
What to watch: full-year 2027 revenue outlook when fourth-quarter results arrive. Because 2026 benefited from $21.5 million of first-half milestones, 2027 revenue will drop unless major partners trigger new phase transitions.
Losses and Dilution Persist Despite Cost Cuts
OmniAb has trimmed its staff and lab costs over the past year, cutting nine-month research and development spending by 15% and general and administrative overhead by 8%. Even so, the business remains deeply loss-making in quarters without large milestone windfalls. Third-quarter operating loss was $16.4 million, and net loss was $15.7 million.
In the third quarter, research and development took up 239% of revenue (down 224 percentage points from a year ago by our math), while general and administrative costs took up 181% (down 121 percentage points). Cash operating expenses, which exclude stock compensation and depreciation, rose 11% from a year ago to $13.7 million. Weighted-average share count also rose 12.7% from a year ago to 129.3 million following last year's equity raise, and the year-end cash plan implies about $9.2 million of cash use in the fourth quarter.
What to watch: fourth-quarter cash operating expenses against the $12.8 million implied by the full-year outlook. Keeping cash costs near $50 million a year is necessary to avoid tapping equity markets again.
Clinical Pipeline Count and Royalties Stall
Three standing concerns around pipeline conversion and product disclosures saw little progress in the third-quarter release.
- Clinical and commercial programs: unchanged from last quarter at 34, even as total active programs grew by 8 to 433.
- Royalty revenue: $355 thousand in the third quarter, down 1.7% from a year ago despite three approved products.
- xPloration unit economics: the release did not disclose how many machines were sold in the quarter or break out recurring consumable sales from hardware.
What to watch: the quarterly 10-Q filing's program additions and terminations table. If partner attrition keeps offsetting new clinical entrants, the 34-program clinical bottleneck will cap near-term milestone potential.
👓 Other Themes
OmniTides Expands Discovery Into Peptides
At its October investor day, the drug-discovery group introduced OmniTides, its "new peptide discovery offering powered by the OmniUltra™ transgenic chicken platform". Peptides are short chains of amino acids that are smaller than standard antibodies. OmniAb uses its genetically engineered chickens to optimize these molecules naturally before partners manufacture them chemically, adding a new service line without building chemical factories.
💲 Other KPIs
Service revenue—fees partners pay OmniAb to run discovery research on their behalf—more than doubled, rising 138.6% from a year ago and 14.6% from last quarter. Growth accelerated after a 10.7% gain in the first quarter and 27.7% in the second, driven by new work on antibody and ion channel programs.
Active partnered drug programs rose by 8 from last quarter and 8.5% from a year ago, while active partners edged up by 1 to 111. Over the past four quarters, annual program growth has held steady between 8.2% and 12.1%, building the long-term funnel for future milestone payments.
🔮 Guidance
Raised. The middle of the range moved up $3 million to $37 million, nearly double last year's $18.7 million. By our math, that leaves $5.2 million for the fourth quarter, down 38.3% from a year ago because 2026 milestones arrived in the first half. It is the third raise this year: +$3.0M, +$3.5M, +$3.0M.
Cut. The company lowered its full-year total operating expense forecast by $1 million at both ends, pointing to a 3.0% decline from last year at the middle of the range. By our math, that leaves $22.3 million of expenses for the fourth quarter, up from $20.4 million in the third quarter.
Cut. Management trimmed its forecast for cash operating expenses—which exclude $18 million of depreciation and amortization and $15 million of stock compensation—by $1 million. By our math, the $52 million middle of the range leaves $12.8 million for the fourth quarter, down 6.8% from the third quarter's $13.7 million.
Raised. The year-end cash target moved up $4 million from the October investor day range (and up $17 million from the second-quarter report). At the $55 million middle of the range, OmniAb will finish 2026 slightly above its $54.0 million starting balance. By our math, that implies $9.2 million of cash use in the fourth quarter.
Unchanged. OmniAb continues to expect a full-year tax rate near 0% because a valuation allowance offsets its deferred tax assets.
New. Alongside the broader commercial rollout, the company issued its first annual sales target for the xPloration screening platform, calling for $2.5 million at the middle of the range (up 232% from 2025). By our math, that leaves $582 thousand for the fourth quarter, compared with $703 thousand in the third.
❓ Key Questions
How much did Eli Lilly pay upfront?
Total deferred revenue jumped by $12.4 million in the third quarter, while cash rose by $12.2 million. Management did not disclose the exact upfront payment from Eli Lilly or how fast it will recognize that sum as service revenue.
How many xPloration machines are now in the field?
OmniAb reported $703 thousand in third-quarter xPloration sales and predicted revenue will double in 2027 and 2028, but stopped disclosing how many instruments it sold or how much recurring revenue each machine generates.
Why did the clinical program count stay flat at 34?
Total active programs grew by 8 to 433, yet clinical and commercial programs stayed at 34. Did zero programs enter human trials this quarter, or did partner trial terminations cancel out new clinical entrants?
Will batoclimab's approval in China bring meaningful royalties?
China's regulator approved batoclimab for generalized myasthenia gravis in October, with commercialization handled by CSPC Pharmaceutical's NBP Pharma. Management has not stated when royalty payments from China will begin or the contracted royalty rate.